- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT04235816
Mejora de la atención a través de la investigación con azitromicina para bebés en África (ICARIA)
Evaluación del impacto en la mortalidad infantil del tratamiento preventivo intermitente con azitromicina más administrado a través del Programa Ampliado de Inmunización en Sierra Leona
Infectious diseases are among the most common causes of mortality in the over 2.5 million children under 5 years of age (U5) who died in 2018 in sub-Saharan Africa (SSA). New approaches to treatment and prevention of these diseases are needed to increase child survival. Sierra Leone has one of the highest rates of under-five child mortality in the world. It is estimated that 32,000 children die each year, the leading causes being neonatal conditions, malaria, pneumonia and diarrhea. In Sierra Leone, the available information on malaria indicates that it accounts for 38% of deaths among under-five children. Reducing the prevalence and impact of the disease among the general population is a major priority of the Ministry of Health and Sanitation (MoHS) of Sierra Leone .
Intermittent Preventative Treatment in infants (IPTi) - the administration of a full course antimalarial treatment to infants at individual timepoints regardless of infection status- has been shown to reduce clinical malaria and anemia in infants in the first year of life . When delivered alongside the Expanded Program on Immunization (EPI), IPTi with Sulphadoxine-pyrimethamine (SP) is a highly cost-effective intervention. . Sierra Leone is currently the only country that implements nationwide the World Health Organization's (WHO) IPTi guideline, which is administered within the first year of life. However, its benefit when expanded into the second year of life remains unknown. Taking the advantage of the inclusion in the EPI program of a booster dose of measles vaccine at 15 months of age, the ICARIA trial will also assess the efficacy of adding a dose of IPTi-SP at this age.
Recent studies show that azithromycin (AZi) - a macrolide antibiotic with some antimalarial effect- is associated with a significant reduction in childhood mortality when used in mass drug administration (MDA) for trachoma elimination in areas of sub-Saharan Africa (SSA) with child mortality rates far beyond Sustainable Development Goals , . However, despite the potential benefit of the intervention several fundamental scientific questions need to be answered before it can be recommended for large-scale implementation.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
In order to generate the conclusive evidence needed to inform policy and accelerate the implementation of this intervention, we propose to carry out a large-scale clinical trial on the impact on all-cause mortality up to 18 months of age of AZi administration through EPI. The potential development of antibiotic and SP resistance, AZi and SP interactions with routine immunizations, as well as the safety and the impact on the health system will be all assessed in the ICARIA trial.
To provide the evidence needed to inform policy and practice and to accelerate the implementation of this intervention, a large-scale clinical trial on the impact on all-cause mortality up to 18 months of age of AZi administration through the World Health Organisation Expanded Program on Immunisation (EPI) will be carried out in Sierra Leone. The clinical trial will be individually randomised, placebo-controlled with a factorial design whereby AZi will be administered alongside routine preventive health interventions of the EPI, such as immunisations and Intermittent Preventive Treatment in infants (IPTi), which is recommended by the WHO for malaria prevention in this age group. The potential development of antibiotic resistance, the interactions with routine immunisations, the safety and the impact on the health system of AZi administration will be all assessed in this trial.
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 3
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Freetown, Sierra Leona
- College of Medicine and Allied Health Sciences
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Parents/guardians have signed the informed consent
- Permanent residence in the study area-health facility catchment area
- Without known allergies to or contraindications to macrolides
- Without known allergies to or contraindications to SP
- Agreement to complete the EPI scheme at the recruitment health facility
- Parents/guardians agree to participate
Exclusion Criteria:
- Residence outside the study area or planning to move out in the following 12 months from enrolment
- Known history of allergy or contraindications to macrolides and/or SP
- Known history of allergy or contraindications to SP
- With signs of any acute illness at the time of recruitment
- Participating in other intervention studies
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Prevención
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Cuadruplicar
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Comparador activo: Group 1
AZi at DTP-1 visit at 6 weeks of age, AZi (plus IPTi) at measles visit at 9 months of age and AZi (plus IPTi) at measles booster visit at 15 months of age. |
Administration of azithromycin during the first 15 months of life through the Expanded Program on Immunisation
Otros nombres:
|
|
Comparador de placebos: Group 2
Placebo at DTP-1 visit at 6 weeks of age, placebo (plus IPTi) at measles visit at 9 months of age and placebo (plus IPTi) at measles booster visit at 15 months of age. |
Administration of placebo during the first 15 months of life through the Expanded Program on Immunisation |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
The rate of all-cause mortality
Periodo de tiempo: 18 months of age
|
all-cause mortality rate at 18 months of age |
18 months of age
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
The cause-specific mortality rate
Periodo de tiempo: 18 months of age
|
Cause-specific mortality rate at 18 months of age |
18 months of age
|
|
Malaria related mortality
Periodo de tiempo: 18 month of age
|
Malaria related mortality at 18 months of age |
18 month of age
|
|
Incidence of all-cause hospital admissions
Periodo de tiempo: Through study completion, 36 months
|
Incidence of all-cause hospital admissions |
Through study completion, 36 months
|
|
Incidence of all-cause outpatient attendances
Periodo de tiempo: Through study completion, 36 months
|
Incidence of all-cause outpatient attendances at the health facilities |
Through study completion, 36 months
|
|
Incidence of confirmed (RDT positive) malaria hospital admissions
Periodo de tiempo: Through study completion, 36 months
|
Incidence of confirmed (RDT positive) malaria hospital admissions at all health facilities |
Through study completion, 36 months
|
|
Incidence of confirmed (blood smear positive/RDT positive) malaria hospital admissions
Periodo de tiempo: Through study completion, 36 months
|
Incidence of confirmed (blood smear positive/RDT positive) malaria hospital admissions at all health facilities |
Through study completion, 36 months
|
|
Frequency and severity of drug adverse reactions
Periodo de tiempo: Through study completion, 36 months
|
Frequency and severity of drug adverse reactions throughout the trial |
Through study completion, 36 months
|
|
Prevalence of macrolide resistance in nasopharyngeal isolates
Periodo de tiempo: Through study completion, 36 months
|
Prevalence of macrolide resistance in nasopharyngeal isolates |
Through study completion, 36 months
|
|
Prevalence of macrolide resistance in the gut bacteria
Periodo de tiempo: Through study completion, 36 months
|
Prevalence of macrolide resistance in the gut bacteria |
Through study completion, 36 months
|
|
Proportion of children with protective antibody responses to specific routine EPI immunizations (measles and yellow fever)
Periodo de tiempo: Through study completion, 36 months
|
Proportion of children with protective antibody responses to specific routine EPI |
Through study completion, 36 months
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Clara Menendez, MD, PhD, Barcelona Institute for Global Health
Publicaciones y enlaces útiles
Publicaciones Generales
- Chen H, Owusu-Kyei K, Fombah AE, Williams J, Garcia-Fernandez C, Rovira-Vallbona E, Bofill A, Quinto L, Figueroa-Romero A, Mac-Abdul F, Samai M, Mayor A, Menendez C. Prevalence of Molecular Markers of Resistance to Antimalarial Drugs Three Years After Perennial Malaria Chemoprevention in Sierra Leone. Gates Open Res. 2025 Oct 8;9:81. doi: 10.12688/gatesopenres.16367.1. eCollection 2025.
- Owusu-Kyei K, Chen H, Chileshe M, Quinto L, Sibley M, Figueroa-Romero A, Llach M, Ramirez M, Bofill A, Samai M, Menendez C; ICARIA Trial Team. Impact of oral azithromycin and intermittent preventive treatment with sulfadoxine-pyrimethamine regimen on child mortality in Sierra Leone: trial protocol for a randomised, two-arm, double-blinded, placebo-controlled clinical trial (ICARIA). Trials. 2024 Sep 27;25(1):626. doi: 10.1186/s13063-024-08443-9.
- Chen H, Montero-Vale M, Owusu-Kyei K, Lara-Munoz A, Rubio-Garcia E, de Pedro-Jove R, Guiral E, Chileshe MN, Williams J, Bofill A, Samai M, Casals-Pascual C, Vila J, Menendez C. Early-life carriage and antibiotic resistance of Streptococcus pneumoniae in infants from Sierra Leone. Front Microbiol. 2026 May 22;17:1822296. doi: 10.3389/fmicb.2026.1822296. eCollection 2026.
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- ICARIA
- OPP1196642 (Otro número de subvención/financiamiento: Bill & Melinda Gates Foundation)
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
producto fabricado y exportado desde los EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .